Safety of Inclisiran: A Disproportionality Analysis from the EudraVigilance Database
<b>Introduction:</b> The discovery of serine protease proprotein convertase subtilisin-kexin type 9 (PCSK9) has revolutionized pharmacological lipid-lowering treatments. The first PCSK9 antagonists (PCSK9-A), evolocumab and alirocumab, were approved in 2015. Targeting PCSK9 synthesis mar...
Sparad:
Huvudskapare: | , , , , , , , , , |
---|---|
Materialtyp: | Bok |
Publicerad: |
MDPI AG,
2024-10-01T00:00:00Z.
|
Ämnen: | |
Länkar: | Connect to this object online. |
Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Internet
Connect to this object online.3rd Floor Main Library
Signum: |
A1234.567 |
---|---|
Exemplar 1 | Tillgänglig |